Maravai Lifesciences Holdings (MRVI) Cost of Revenue (2020 - 2026)

Maravai Lifesciences Holdings' Cost of Revenue history runs 7 years deep, the most recent figure standing at $32.1 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 17.86% year-over-year to $32.1 million; the TTM figure through Mar 2026 stood at $144.8 million (down 4.55% YoY), while the FY2025 annual figure was $151.8 million, up 0.58% from the prior year.
• Cost of Revenue for Q1 2026 stood at $32.1 million, down from $37.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $53.3 million in Q4 2022, with the low at $32.1 million in Q1 2026.
• The 5-year median for Cost of Revenue is $37.5 million (2022), against an average of $38.4 million.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue soared 36.06% in 2022, then slumped 34.07% in 2023.
• Maravai Lifesciences Holdings' Cost of Revenue stood at $53.3 million in 2022, then tumbled by 34.07% to $35.1 million in 2023, then climbed by 5.87% to $37.2 million in 2024, then slipped by 0.39% to $37.0 million in 2025, then declined by 13.2% to $32.1 million in 2026.
• Business Quant data shows MRVI's Cost of Revenue at $32.1 million in Q1 2026, $37.0 million in Q4 2025, and $36.0 million in Q3 2025.